Microbiome SER-155
Seres Therapeutics Cuts 25% of Workforce Following FDA Feedback on Microbiome Therapy Trial
Seres Therapeutics; layoffs; microbiome; FDA feedback; SER-155; phase 2 trial; workforce reduction; biopharma; clinical studies; cash runway